Liquidia (LQDA) is back in focus after the company outlined four new poster presentations at the PHA 2026 International PH Conference, spotlighting fresh YUTREPIA data and broader pulmonary hypertension care insights.

The PHA 2026 conference update comes at a time when Liquidia’s momentum has been strong, with a 30 day share price return of 26.12% and a 5 year total shareholder return of 2,737.94%. Together, these figures point to sentiment that has shifted meaningfully over both the short and longer term.

If the YUTREPIA data has you watching Liquidia more closely, it may also be a good time to see what else is moving in rare disease and specialty medicine by checking out 39 healthcare AI stocks

With Liquidia stock up sharply over the past year and trading around $71.80 against a lower analyst price target, the key question is whether the large intrinsic discount hints at mispricing or whether the market is already factoring in future growth.

Most Popular Narrative: 63.2% Overvalued

The most followed valuation narrative for Liquidia compares a fair value of $44.00 to the current $71.80 share price and treats the gap as a material premium that needs strong execution to be justified.

Progress across the pipeline, particularly the move toward a pivotal study for L606 and upcoming R&D Day data for patients treated up to one year, builds a second potential pulmonary hypertension asset on top of YUTREPIA. This can diversify future revenue sources and create operating leverage if multiple products share the same commercial and manufacturing infrastructure.

Curious what earnings profile has to emerge for that fair value to make sense? The narrative leans on rapid revenue compounding, rising margins and a future profit multiple that assumes investors stay confident in this rare disease story.

Result: Fair Value of $44.00 (OVERVALUED)

However, there is still a risk that payer contracts, voucher usage and manufacturing expansion will not translate into the analyst earnings and revenue assumptions underpinning Liquidia.

Another View: SWS DCF Puts Liquidia Stock In A Different Light

While the consensus narrative tags Liquidia as 63.2% overvalued against a $44.00 fair value, the SWS DCF model points in the opposite direction, with Liquidia trading at $71.80, which is 75.7% below an estimated future cash flow value of $295.50. That leaves a different question: which story do you trust more, analyst multiples or long term cash flows?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Liquidia for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such a split between multiples and cash flow signals around Liquidia, it makes sense to move quickly, review the underlying data and weigh both the upside and the downside using 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Liquidia stock?

If Liquidia has sharpened your focus on opportunity, do not stop here. Use targeted stock lists to pressure test your thinking and spot ideas others might miss.

• Zero in on quality opportunities trading below their estimated worth by scanning 47 high quality undervalued stocks, which combines solid fundamentals with attractive pricing.
• Strengthen your portfolio’s foundations by reviewing the solid balance sheet and fundamentals stocks screener (48 results) and focusing on companies with healthier financial footing.
• Get ahead of the crowd by scanning the screener containing 20 high quality undiscovered gems before they sit squarely on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.